NVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Novartis (NVS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has a stable growth outlook, positive technical indicators, and strong dividend history, making it suitable for long-term holding. Despite some recent financial challenges, the company's pipeline and strategic initiatives provide a solid foundation for future growth.
The technical indicators are moderately bullish. The MACD is positive and contracting, RSI is neutral at 63.997, and the moving averages show a bullish alignment (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels, with the next resistance at 167.316 and 169.334.
Novartis has a strong dividend history, increasing dividends annually since 1996, making it attractive for income-focused investors.
The company is advancing five new drugs and has shown resilience despite patent expirations.
Positive clinical results for Pluvicto and plans for a new manufacturing site in Texas indicate growth potential.
Recent financial performance shows a drop in net income (-14.51% YoY) and EPS (-10.71% YoY), which could concern some investors.
Analysts have mixed views, with some downgrades and a few price target reductions.
In Q4 2025, revenue increased by 2.23% YoY to $13.86 billion, but net income dropped by 14.51% YoY to $2.41 billion. EPS decreased by 10.71% YoY to 1.25, and gross margin fell slightly to 74.44%. While revenue growth is positive, declining profitability metrics highlight some near-term challenges.
Analysts have mixed ratings on Novartis. Recent upgrades include Deutsche Bank and JPMorgan raising price targets and maintaining Buy/Overweight ratings. However, DZ Bank downgraded the stock to Hold, and Citi slightly reduced its price target. The overall sentiment leans positive, with confidence in the company's growth potential through 2030.
